newsfilter
← Latest News
GlobeNewswire·

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity